{"contentid": 488233, "importid": NaN, "name": "Ontozry receives EC approval to treat drug-resistant focal-onset seizures in adults", "introduction": "Privately-held Angelini Group has announced that the European Commission (EC) has granted marketing authorization for Ontozry (cenobamate) for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adults who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products.", "content": "<p>Privately-held Italy-based Angelini Group has announced that the European Commission (EC) has granted marketing authorization for Ontozry (cenobamate) for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adults who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products.</p>\n<p>The EC marketing authorization is valid in all European Union (EU) member states plus Iceland, Norway and Liechtenstein. Ontozry is currently being reviewed via the reliance route by the UK&rsquo;s Medicines and Healthcare Regulatory Agency (MHRA).</p>\n<p>Pierluigi Antonelli, chief executive of Angelini Pharma, said: &ldquo;Ontozry will be a welcome new treatment option in Europe for adults who have not yet been able to control their focal-onset seizures with available treatments.</p>\n<p>&ldquo;Treatment-resistant epilepsy has a devastating effect on patients and their families, and we are proud to help address this urgent health challenge.</p>\n<p>&ldquo;Angelini Pharma looks forward to bringing Ontozry to patients across Europe and will continue to address the needs of patients with central nervous system disorders through its product portfolio and pipeline.&rdquo;</p>\n<p>Cenobamate, which was discovered by Korea's SK Biopharmaceuticals and SK life science, was approved by the US Food and Drug Administration for the treatment of partial-onset seizures in adults in 2019, and is commercially available in the USA under the brand name Xcopri.</p>\n<p>&nbsp;</p>", "date": "2021-04-01 12:40:00", "meta_title": NaN, "meta_keywords": "Ontozry, treatment, seizures, adults, focal-onset, Angelini, authorization, European, marketing, cenobamate, approval, treat, drug-resistant, receives, MHR", "meta_description": "Privately-held Angelini Group has announced that the European Commission (EC) has granted marketing authorization for Ontozry (cenobamate) for the adjunctive tr", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-01 12:22:11", "updated": "2021-04-01 12:41:30", "access": NaN, "url": "https://www.thepharmaletter.com/article/ontozry-receives-ec-approval-to-treat-drug-resistant-focal-onset-seizures-in-adults", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "angelini_big.jpg", "image2id": "angelini_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "CNS Diseases, Neurological", "topic_tag": "European Medicines Agency, Focus On, Regulation", "geography_tag": "Europe, Italy, South Korea", "company_tag": "Angelini, SK biopharmaceuticals", "drug_tag": "Ontozry, Xcopri", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-01 12:40:00"}